A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults (NCT04661839), a randomized phase 1 study. The primary outcome is Subjects With Adverse Events (AEs) up to 3 Days Post-dosing.

2. Clinical Question

This is a safety and pharmacokinetics study, not a trial designed in the registry record around a clinical benefit comparison. Its primary endpoint counts participants with adverse events during the stated early post-dose period. The registry also lists pharmacokinetic outcomes concerning SARS-CoV-2 antibodies after COVID-HIGIV, including maximum observed concentration, several measures of antibody exposure over time, and a trough concentration at 28 days.

The study enrolled healthy adults and assigned participants to a single dose of one of the three COVID-HIGIV dose levels or to saline placebo. The brief description specifies safety and pharmacokinetic follow-up for 84 days after administration. The clinical question is therefore about the short-term safety count in the primary endpoint and the broader safety and antibody concentration observations over follow-up. The posted record does not report comparative estimates or a statistical test for the primary endpoint, so it cannot answer whether the groups differ with a stated degree of statistical precision.

3. Trial Design

The registry describes a phase 1, randomized, double-blind, placebo-controlled, parallel-group study. Masking is recorded as quadruple. Participants were assigned to a single intravenous infusion of COVID-HIGIV at 100 mg/kg, 200 mg/kg, or 400 mg/kg, or to saline placebo. The study’s stated purpose was to evaluate safety and pharmacokinetics in healthy adults.

The registry lists enrollment of 28. In the posted safety groups, the numbers at risk for the reported serious and other adverse-event summaries are 8, 8, 7, and 4 across the three dose levels and placebo, respectively. Those group figures describe the posted safety summaries; the record does not explain the relationship between the enrollment figure and the group counts. It also does not report a participant flow account here, such as the numbers screened, randomized, treated, or followed through each assessment.

The study start is recorded as 2020-12-24 and primary completion as 2021-07-27. Its status is completed. The brief description states that safety and pharmacokinetic follow-up continued for 84 days after administration. The primary endpoint concerns adverse events through Day 4, while the secondary outcomes address antibody pharmacokinetic parameters over specified periods.

Randomization and masking are design features intended to limit systematic differences and the influence of knowledge about assigned treatment. In general, randomization can support fair group comparisons when allocation and follow-up are well described, while masking can reduce certain assessment and reporting influences. The registry record does not report the allocation procedure or specific masking roles, and it does not provide enough detail to assess how those procedures were implemented. It also does not report a sample-size justification.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety population includes all subjects who received any amount of study treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Data is from the safety population which includes all subjects who received any amount of study treatment.

6. Primary Endpoint

The registry lists the primary outcome as Subjects With Adverse Events (AEs) up to 3 Days Post-dosing, measured over Day 1 through Day 4.

The primary endpoint is the number of participants with adverse events and the severity of those events up to 3 days after dosing. Its timeframe is recorded as Day 1 through Day 4. The outcome unit is participants, and the stated analysis population is the safety population: participants who received any amount of study treatment.

This type of endpoint is used in an early-phase study to summarize observed safety events after administration. Counting participants rather than event episodes indicates how many people experienced an event, regardless of whether an individual had more than one event. The endpoint also specifies severity, although the posted record does not give severity categories or event-by-event details for this primary outcome.

In general, early safety counts can describe what was observed over a specified period, but they do not by themselves establish that an event was caused by treatment. Interpretation depends on the event definitions, ascertainment procedures, follow-up completeness, and the size and composition of each group. Those details are not reported in the registry record. The record also does not provide a primary-endpoint comparison, confidence interval, or statistical test. Accordingly, this endpoint can be described as an observed count, but the posted information does not quantify the precision of a between-group difference.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The methods information in the registry record is limited. It identifies a randomized, quadruple-masked, parallel-group study with three COVID-HIGIV dose groups and a saline placebo group. The primary outcome is a count of participants with adverse events, and the stated population is the safety population. The record lists outcome measures but no analyses. It does not report the statistical methods used to analyze the primary outcome or the pharmacokinetic outcomes.

What do the event counts represent?

The unit for the primary endpoint is participants. In general, a participant-level count records whether each person experienced at least one event in the period of interest. It is different from a count of all event episodes, because one participant can experience multiple events. The registry’s group summaries for other adverse events are also presented as numbers of participants affected and numbers at risk. They are descriptive counts, not estimates of an adjusted treatment effect.

For a binary outcome such as whether a participant had an event, a comparative analysis could use a difference or ratio between groups, potentially with an interval describing uncertainty. The registry record does not report such an estimate, its confidence interval, or a test result for this primary endpoint. No such comparison should be inferred from the raw counts alone. General statistical methods for sparse binary outcomes may behave differently depending on the method and data structure, but the record does not say which method, if any, was used.

What does randomization contribute?

In general, random assignment aims to make treatment groups comparable with respect to factors known and unknown at baseline. This supports causal interpretation of a properly conducted comparison, but randomization does not guarantee that small groups will have similar characteristics. The record states that allocation was randomized, but it does not report the sequence-generation or concealment procedures, baseline characteristics, or group-specific participant flow. Those omissions limit an assessment of comparability from this record alone.

Masking is recorded as quadruple. In general, masking can reduce the risk that knowledge of treatment assignment influences care, event reporting, or assessment. The registry record does not specify which roles were masked or how masking was maintained. The label therefore describes the registered design, not proof that every possible source of bias was eliminated.

How should the pharmacokinetic outcomes be understood?

The listed secondary outcomes concern body-weight-normalized antibody pharmacokinetic parameters after COVID-HIGIV. They include maximum observed concentration, area under the concentration-time curve to the last quantifiable concentration, area under the curve extrapolated to infinity, area under the curve through 14 days, area under the curve through 28 days, and trough concentration at 28 days. In general, maximum concentration summarizes the highest observed concentration, while area under the curve summarizes concentration over time. A trough concentration is a specified low-point measurement within the dosing interval or follow-up schedule. These are descriptions of the listed measures, not claims about their values.

The registry record does not report numeric results or analysis methods for these pharmacokinetic measures in the information. It does not state how values below quantification limits, missing samples, or departures from planned sampling were handled. It also does not report model assumptions, transformations, or methods for estimating exposure. These details matter because pharmacokinetic summaries depend on the timing and completeness of measurements as well as the analysis choices.

What do the planning illustrations mean?

The sample-size section presents planning illustrations based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is expressed as a stated fraction of the observed effect. These are planning illustrations, not the trial’s own design justification and not observed power. In general, sample-size planning asks how much information might be needed to detect a specified effect under stated assumptions. It does not show the probability that this completed study has reached a meaningful conclusion, and it cannot repair the absence of a reported primary comparison.

The registry record does not report the trial’s sample-size justification, interim analyses, or detailed statistical analysis plan. Since the posted record lists no analyses, the design features and descriptive counts should not be mistaken for a complete account of the planned or conducted statistical analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 20 outcome measures, including the primary adverse-event measure and secondary pharmacokinetic measures. It does not report a multiplicity strategy, such as a hierarchy, adjustment, or prespecified rule for interpreting several outcomes together. The record also lists no analyses. Therefore, it is not possible to determine from this information how multiple outcomes were handled in inferential testing, or whether any such testing was conducted.

In general, multiplicity matters when many hypotheses are assessed because repeated testing can increase the chance of a nominally notable result arising by chance. That concern is relevant as a general statistical principle, not as a claim that this trial conducted multiple significance tests. The registry record does not provide the results needed to evaluate such tests.

Missing-data handling is not reported in the registry record. This includes whether all randomized or treated participants completed each assessment, how missing adverse-event information was handled, and how missing pharmacokinetic samples or unquantifiable concentrations were treated. The stated primary analysis population is the safety population, defined as participants who received any amount of study treatment. The record does not provide an intention-to-treat analysis population, a per-protocol population, or a detailed account of exclusions from any analysis.

These absences do not establish that data were missing or that a particular analysis approach was used. They mean that readers cannot assess completeness or reproduce the analysis from the registry record. The group counts should therefore be interpreted as the posted summaries, without assuming a missing-data method or an analysis population beyond the one explicitly named for the primary endpoint.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pyrexia (25.0%).

The serious adverse-event summary reports the number of participants affected and the number at risk in each group. It lists 0 of 8 for COVID-HIGIV 100 mg/kg, 0 of 8 for COVID-HIGIV 200 mg/kg, 0 of 7 for COVID-HIGIV 400 mg/kg, and 1 of 4 for saline placebo. These are the posted counts; the record does not give a confidence interval or a statistical comparison.

These summaries should not be read as proof that serious events cannot occur in a treatment group, nor as proof of a difference between treatment and placebo. In general, small groups provide limited precision for uncommon events. The record does not provide enough detail to evaluate the event narratives, seriousness criteria, timing, or causal attribution. Its top serious-event term is Pyrexia at 25.0%, but the registry summary does not explain the denominator or identify a group for that term in this information.

Other adverse events are reported separately: 3 of 8, 6 of 8, 6 of 7, and 3 of 4 across the dose groups and placebo. They should not be combined with the serious-event counts; they are a different summary. The record does not supply event-level detail that would explain the types or severity of these other events.

12. What the Result Does, and Does Not, Mean

The record establishes that this was a completed, randomized phase 1 study of single-dose COVID-HIGIV and saline placebo in healthy adults, with safety and pharmacokinetics as its stated focus. It reports the primary endpoint definition, the groups, and descriptive counts for serious and other adverse events. It also lists secondary antibody pharmacokinetic outcomes and states an 84-day follow-up period.

Those details describe the study and its posted summaries. They do not establish a treatment effect, a dose-response relationship, or a causal explanation for any event. The registry record does not provide a formal primary-outcome comparison, confidence intervals, p-values, or numeric pharmacokinetic results in the information. Consequently, the counts cannot be translated into a precise estimate of the difference between COVID-HIGIV and placebo.

In general, a nonsignificant result, if one were reported, would not by itself establish that treatments are equivalent. Here, no primary inferential result is posted in the record. Likewise, an absence of recorded serious events in some small groups is not evidence that the risk is zero. The observed counts are limited to participants represented in the reported safety summaries and the stated follow-up context.

The sample-size section on the page contains planning illustrations, not evidence about the strength or success of the trial’s design. They are not observed power and do not substitute for an estimate with its uncertainty. The registry record does not report the sample-size justification used by the investigators. Overall, the appropriate interpretation is descriptive: the posted results show the event counts in the summarized groups, while leaving the precision of between-group differences and the pharmacokinetic findings unreported.

13. Why This Trial Matters Statistically

This study illustrates a common statistical challenge in early-phase research: the main purpose is to characterize safety and pharmacokinetics, while the number of participants in each group is limited. In general, such studies can provide useful descriptive information about events observed after dosing and the planned measurements of drug-related concentrations. But small group counts have limited ability to characterize uncommon events or precisely compare groups.

It also illustrates why endpoint definitions and analysis populations matter. The primary endpoint counts participants with adverse events through the early post-dose period, and the stated safety population includes people who received any amount of study treatment. The record separately identifies longer safety and pharmacokinetic follow-up. Keeping those timeframes and populations distinct helps avoid treating different summaries as if they answer the same question.

Another statistical point is the distinction between an observed count and an inferential result. The registry contains event counts, but no analysis results for the primary endpoint. Without an estimated contrast and uncertainty interval, readers cannot assess how compatible the data are with a range of possible differences. Counts can be transparent and informative as descriptions while remaining insufficient for strong comparative conclusions.

Finally, the record lists multiple pharmacokinetic outcomes but does not provide their values or analysis methods. That gap highlights the importance of complete reporting: outcome names indicate what was intended to be assessed, but they do not reveal the observed concentration profiles or their precision. The study matters statistically as an example of how design labels, outcome definitions, descriptive safety summaries, and inferential evidence each contribute different information—and should not be conflated.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limits affect interpretation of the registry record. The enrollment figure is 28, while the posted safety summaries show group-specific numbers at risk of 8, 8, 7, and 4. The record does not explain the relationship between enrollment and those safety-group counts, nor provide a participant flow account for randomization, treatment, completion, and analysis. This makes it difficult to understand how complete each summary is.

The primary endpoint is described as adverse events and severity through 3 days post-dosing, with a timeframe of Day 1 through Day 4. However, the posted summary does not give severity results by group, event-level descriptions, or a comparative estimate. The record does not report confidence intervals, p-values, or an analysis method for the primary endpoint. Thus, its descriptive counts cannot establish the precision of differences between groups.

Although pharmacokinetic outcomes are listed, the record gives no numerical concentration or exposure results. It also does not report the timing and completeness of sample collection, handling of missing samples, or analysis methods for these outcomes. The top serious-event term is listed as Pyrexia at 25.0%, but the denominator and group association are not explained in this summary.

The registry does not report the detailed statistical analysis plan, sample-size justification, interim analyses, multiplicity approach, or missing-data methods. Baseline characteristics and details of allocation implementation are also not reported. These are limits of what can be established from the registry record, not evidence that procedures or analyses were absent. The findings are further bounded by the study’s healthy-adult population, single-dose design, and 84-day follow-up description; the record does not establish how these results would apply beyond the studied participants or observation period.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults — NCT04661839.
• Registry record last updated 2025-06-08; status last verified 2025-05.
• Results first posted 2023-02-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

This completed phase 1 study evaluated single-dose COVID-HIGIV at 100 mg/kg, 200 mg/kg, or 400 mg/kg against saline placebo in healthy adults. The registry records randomized allocation, quadruple masking, a parallel-group design, and enrollment of 28. Safety and pharmacokinetics were the stated focus, with follow-up described as 84 days after administration.

The primary endpoint counted participants with adverse events and their severity through Day 1 through Day 4, described as up to 3 days after dosing. Posted safety summaries include serious and other adverse-event counts by group. The record lists 20 outcome measures, including antibody concentration and exposure measures, but no analyses. It does not report a primary-endpoint comparison, uncertainty intervals, numeric pharmacokinetic results, or detailed methods for missing data and multiplicity. The event counts should therefore be read descriptively, not as a precise comparative estimate.